Amyloidosis Treatment Market

The global market value of the amyloidosis treatment market was valued at USD 8.1 billion in 2023 and is projected to grow at a CAGR of 7.3% during the forecast period. Amyloidosis is an unwanted build-up of protein deposits in various body organs, and it causes damage to body organs. These deposits disrupt the normal functioning of body organs.  Genetic conditions, chronic inflammatory diseases, and certain cancers are the real cause behind amyloidosis.

Innovations in imaging techniques like Cardiac MRI, and PET Scans with amyloid-specific tracers, have improved early detection of amyloidosis. Increased investments in Research and Development by pharmaceuticals and biotechnology firms is driving growth significantly in the market. Growing aging population worldwide is the key reason behind the growth of amyloidosis treatment market.

Growth Drivers

Increasing awareness about rare diseases and early treatment is the key factor behind the market growth. Rising healthcare expenditures and an increasing number of patients with genetic mutation in blood cell DNA is the key factors behind the growth in the market. An increasing number of patients with chronic diseases like rheumatoid arthritis, and other diseases which affect lung, kidney, and liver are driving the market growth significantly. Early and accurate diagnosis of amyloidosis is essential for effective treatment. Recent advancements in diagnostic technologies, such as imaging techniques and biomarker identification, have significantly improved the detection and diagnosis of amyloidosis.

The increasing geriatric population all over the world, which is more susceptible to amyloidosis is driving growth in the market significantly. Heavy investments made by the government initiatives for research and development aiming at early diagnosis and treatment are driving market growth significantly. Rising disposable income, and growth in healthcare infrastructure in all over the world is driving demand in the market significantly.

Segmentation

Amyloidosis Treatment Market by Treatment Type Segmentation

·         Chemotherapy

·         Immunosuppressive Drugs

·         Transplantation

·         Supportive Care

·         Surgery

·         Others

Amyloidosis Treatment Market by End-user Segmentation

·         Hospitals & Clinics

·         Ambulatory Surgical Centers

·         Home Care Settings

·         Others

By Region

·         Asia Pacific

·         North America

·         Latin America

·         Europe

·         Middle East and Africa

Amyloidosis Treatment Market by Treatment Type Segmentation

Based on treatment type, the amyloidosis treatment market is segmented into chemotherapy, immunosuppressive drugs, transplantation, supportive care, surgery, and others. Chemotherapy is the leading segment in the market. Chemotherapy is the leading segment due to its effectiveness in targeting and destroying the abnormal plasma cells that produce amyloid proteins, thus reducing the production of these harmful proteins.

Transplantation is another growing segment in the case of severity of the disease. Patients with advanced disease stages have increasingly preferred transplantation for its effectiveness in managing amyloidosis. Transplantation, such as autologous stem cell transplantation (ASCT), can significantly improve patient outcomes by replacing damaged cells with healthy ones. 

Increasing demand for surgery in the case of chronic diseases is one of the key reasons behind the significant growth in the market. Rising healthcare expenditure with increasing awareness about rare diseases and their treatment is the key factor behind the significant growth in the market.

Amyloidosis Treatment Market by End-User Segmentation

Based on the end users, the amyloidosis treatment market is segmented into hospitals and clinics, ambulatory surgical centers, home care settings, and others. Hospitals are the leading market segment and are expected to dominate the market during the forecast period. A rising number of patients with amyloidosis belong to the group of geriatric people, who prefer to have specialized healthcare treatment. Hospitals are well-equipped and often blessed with the most skillful doctors. The growing healthcare sector has inspired patients to even go for transplantation, which is only possible in hospitals and clinics.

Regional Outlook

Based on the regions, the amyloidosis treatment market is analyzed into 5 regions: Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. Europe is the leading region in the amyloidosis treatment market and is expected to dominate the market during the forecast period. Europe is witnessing significant growth due to a well-established healthcare infrastructure with wide access to advanced diagnostic tools.

Increasing awareness among the people to identify and treat rare diseases with full efficacy is spurring the market growth. European countries like Germany, France, Italy, and the UK have more structured programs for rare disease awareness, leading to a better diagnosis rate. The presence of many key pharmaceutical and biotechnology firms in the region is the key factor behind the market growth. Europe has a robust network like Eurorids, and European Reference Networks facilitate collaboration in research and clinical practices for rare diseases, accelerating treatment development.

North America is expected to dominate the market during the forecast period, while the Asia-Pacific region is an emerging one. Since the United States of America has the largest health expenditure globally, it enables access to cutting-edge therapies and diagnostics. The region is a hub for many biopharma diagnostic companies actively developing treatments for amyloidosis. The U.S. Food and Drug Administration has approved it for amyloidosis. Companies like Pfizer have worked efficiently in this regard. Increasing awareness among kids about diseases and their treatment is driving growth significantly in the market. Rising healthcare investment in countries like China, Japan, South Korea, Singapore, and India is the key reason behind the market growth in the Asia Pacific region. The increasing geriatric population in the region is the key cause behind the significant growth in the market.

The Asia Pacific region is expected to witness moderate growth during the forecast period. Rising awareness about rare diseases in countries like China, India, South Korea, and Japan is driving the market significantly. The aging population, rising chronic disease rates, and improving healthcare infrastructure in the region are the key factors behind the significant growth in the market. Due to its large and growing population, China is the key player in the region. The presence of key players in the market plays a significant role in market growth.

Key Players

·         Pfizer Inc.

·         Johnson & Johnson Services, Inc.

·         GSK plc

·         Takeda Pharmaceutical Company Limited

·         Amgen Inc.

·         Bristol-Myers Squibb Company

·         Novartis AG

·         F. Hoffmann-La Roche Ltd

·         Merck KGaA

·         Sanofi

·         Alnylam Pharmaceuticals, Inc.

·         Other Players